{"entity":{"id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","aka":[],"tldr":"A phase 3 trial of Sacituzumab govitecan and Capecitabine in HR-positive / HER2-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy is a phase 3 interventional study registered as NCT05840211 by Gilead Sciences, with 654 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel and Capecitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05840211","url":"https://clinicaltrials.gov/study/NCT05840211"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-govitecan","capecitabine"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05840211","phase":"3","setting":"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy","sponsor":"Gilead Sciences","enrolled":654,"outcomes":[]},"route":"/trials/nct05840211/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}